JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Flt-3 ligand (Flt-3L) is a hematopoietic cytokine whose activities are mediated by binding to the transmembrane glycoprotein Flt-3. The predominant human Flt-3L isoform is a transmembrane protein that can undergo proteolytic cleavage to generate a soluble form of the protein. Flt-3L is widely expressed in various human and mouse tissues. Flt-3L has been shown to synergize with a wide variety of hematopoietic cytokines to stimulate the growth and differentiation of early hematopoietic progenitors.
This product is produced from E. coli and is manufactured in a facility that does not use or process beta-lactam containing materials. No animal- or human-derived materials were used during manufacturing or as ingredients. This product is manufactured, tested, and released in an ISO 9001:2015 certified facility and follows cGMP practices. USP chapter <1043> for ancillary materials considered in the manufacture of this product.
> 97% by reducing and non-reducing SDS-PAGE
ED50 < 5 ng/ml, determined by dose-dependent proliferation of OCI-AML5 cells.
~1.6 x 103 IU/µg, which is calibrated against the recombinant Human FLT-3 Ligand WHO International Standard (NIBSC code 96/532).
< 0.05 EU/µg using USP <85> / EP 2.6.14
Lyophilized vial is shipped at ambient temperature. Immediately upon receipt, store unopened vial at -20°C (manual defrost freezer) or -80°C for up to 36 months.
For ex vivo use only. Not for injection or diagnostic procedures. The safety and efficacy of this product in diagnostic or other clinical uses has not been established.